Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 28;6(4):730-738.
doi: 10.3889/oamjms.2018.148. eCollection 2018 Apr 15.

Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities

Adegbenro Omotuyi John Fakoya  1 , Princess Omenyi  1 , Precious Anthony  1 , Favour Anthony  1 , Precious Etti  1 , David Adeiza Otohinoyi  1 , Esther Olunu  1
Affiliations
Review

Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities

Adegbenro Omotuyi John Fakoya et al. Open Access Maced J Med Sci. .

Abstract

Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis are adverse hypersensitivity reactions that affect the skin and mucous membranes. They are characterised by erythematous macules and hemorrhagic erosions of the mucous membranes. Epidermal detachments of varying degrees of severity also occur in these conditions. Various aetiologies are associated with these conditions, with adverse drug reaction being the most common. Though the worldwide incidence of these conditions is recorded as low, diverse types of medication are being observed to lead to these conditions. This review compiles information on the details of Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, the pathophysiology, therapeutic management, and largely considers the drug-induced etiologies associated with these conditions.

Keywords: Adverse drug reaction; Drug hypersensitivity; Mucous membranes; Skin; Stevens-Johnson Syndrome; Toxic Epidermal Necrolysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient with SJS/TEN caused by Trimethoprim -Sulfamethoxazole, before the commencement of therapy
Figure 2
Figure 2
Patient with SJS/TEN caused by Nevirapine responding to therapy
See this image and copyright information in PMC

References

    1. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7:803–813. https://doi.org/10.1586/eci.11.66. PMid:22014021. - PubMed
    1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol. 1993;129:92–96. https://doi.org/10.1001/archderm.1993.01680220104023. - PubMed
    1. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486. https://doi.org/10.1038/428486a. PMid:15057820. - PubMed
    1. Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: Review of pathogenesis and management. Journal of the American Academy of Dermatology. 2012;66(6):995–1003. https://doi.org/10.1016/j.jaad.2011.09.029. PMid:22169256. - PubMed
    1. Schwartz R, McDonough P, Lee B. Toxic epidermal necrolysis. Journal of the American Academy of Dermatology. 2013;69(2):187, e1-187, e16. https://doi.org/10.1016/j.jaad.2013.05.002. PMid:23866879. - PubMed

LinkOut - more resources